PP
ALPN

Paloma Partners’s Alpine Immune Sciences Inc ALPN Stock Holding History

Paloma Partners’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-5,670
Closed -$105K – 2194
2016
Q2 		$105K Buy
+5,670
New +$101K ﹤0.01% 2073

Other funds holding ALPN

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Paloma Partners's ALPN Position: Q3 2016 in Review

Paloma Partners sold out of Alpine Immune Sciences Inc (ALPN) in Q3 2016, closing a stake of 5,670 shares — an estimated $105K sold.

Paloma Partners first reported a position in ALPN in Q2 2016 and held it in 1 quarter. The position peaked at $105K in Q2 2016. 50 funds tracked by Wall St. Rank hold ALPN as of Q3 2016.

  • Paloma Partners reported no remaining Alpine Immune Sciences Inc position as of Q3 2016 after selling out during the quarter.
  • Paloma Partners sold 5,670 Alpine Immune Sciences Inc shares in Q3 2016, an estimated $105K.
  • Paloma Partners first reported a position in Alpine Immune Sciences Inc in Q2 2016 and held it in 1 quarter.
  • Paloma Partners's Alpine Immune Sciences Inc position peaked at $105K in Q2 2016.
  • 50 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q3 2016.

Based on Paloma Partners's 13F filing for Q3 2016, filed 14 Nov 2016.